Smith & Nephew plc (LON:SN)’s share price fell 0% on Wednesday . The company traded as low as GBX 1,340 ($17.62) and last traded at GBX 1,325 ($17.43). 3,048,861 shares were traded during mid-day trading, a decline of 16% from the average session volume of 3,640,000 shares. The stock had previously closed at GBX 1,325 ($17.43).
A number of research firms recently weighed in on SN. Deutsche Bank AG upped their price target on Smith & Nephew plc from GBX 1,200 ($15.78) to GBX 1,315 ($17.30) and gave the stock a “hold” rating in a report on Monday, October 23rd. J P Morgan Chase & Co increased their target price on Smith & Nephew plc from GBX 1,361 ($17.90) to GBX 1,382 ($18.18) and gave the company a “neutral” rating in a report on Thursday, October 19th. Jefferies Group LLC reissued a “buy” rating and set a GBX 1,515 ($19.93) target price on shares of Smith & Nephew plc in a report on Monday, November 6th. Citigroup Inc. reissued a “sell” rating and set a GBX 1,160 ($15.26) target price on shares of Smith & Nephew plc in a report on Thursday, October 12th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a GBX 1,380 ($18.15) target price on shares of Smith & Nephew plc in a report on Monday, September 11th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company’s stock. Smith & Nephew plc presently has a consensus rating of “Hold” and an average price target of GBX 1,302.83 ($17.14).
TRADEMARK VIOLATION WARNING: “Smith & Nephew plc (SN) Trading Down 0%” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/15/smith-nephew-plc-sn-trading-down-0.html.
Smith & Nephew plc Company Profile
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.